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N
early 30 years after the first 
cases of AIDS were reported 
[1] and HIV identified as the 
causative agent, Africa today bears a 
disproportionate burden of the disease. 
Sub-Saharan Africa has just over 10% 
of the world’s population but is home 
to more than 65% of the 33 million 
people in the world estimated to be 
living with HIV/AIDS. The annual rate 
of new infections continues to rise, with 
an estimated 2.5 million people newly 
infected in 2007 [2]. 
Although newer initiatives aimed 
at providing universal access to 
antiretroviral  therapy in Africa are 
ongoing, most Africans receive neither 
treatment nor adequate care [3]. 
Relatively few HIV-infected patients in 
sub-Saharan Africa (about 1 million) 
are currently receiving antiretroviral 
treatment [4], and many more new 
cases are occurring each year [2]. It is 
thus evident that treatment alone will 
not control the spread of the disease 
and that a vaccine is our best hope of 
halting this pandemic. 
In the history of infectious 
diseases, effective vaccines are critical 
public health tools to control and 
prevent diseases. Developing an 
effective HIV vaccine is proving to 
be one of the greatest challenges in 
biomedical research. The need for 
a simple, safe, effective, affordable, 
and equitably distributed preventive 
HIV vaccine to complement existing 
HIV/AIDS prevention, treatment, 
and care programs is greater than 
ever. It is probable that vaccines 
will form part of future innovative 
interventions including microbicides 
and circumcision, used in conjunction 
with other more traditional prevention 
interventions.
What Is AAVP?
An African response—the genesis 
of AAVP. AAVP was created in 2000 
within the global context of relatively 
little attention being paid to Africa’s 
need for an HIV vaccine. While an HIV 
vaccine has always been considered a 
global public good, most laboratory 
and clinical activities prior to 2000 were 
conducted in the industrialized world 
with candidate vaccines that were not 
based on strains circulating in Africa. 
AAVP was created with the specific 
intention of mobilizing support and 
advocating for a more Africa-focused 
vaccine agenda. In 2000, representative 
African scientists met in Nairobi to 
create AAVP and issued a declaration—
“An African Appeal for an AIDS 
Vaccine” [5]. 
The mission of AAVP is to advocate 
for and support a coordinated 
international effort to promote 
the development of and future 
access to HIV vaccines suitable for 
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Summary Points
sÈ 4HEÈ!)$3ÈPANDEMICÈCONTINUESÈTOÈ
be the most serious public health 
challenge facing the world today, 
and Africa bears an overwhelming 
proportion of infections, with 
unprecedented medical and 
socioeconomic consequences. 
sÈ 4HEÈBESTÈHOPEÈTOÈENDÈTHEÈ!)$3È
pandemic remains the development 
of an effective HIV vaccine, and its 
distribution to all communities. 
sÈ 4HEÈ!FRICANÈ!)$3È6ACCINEÈ0ROGRAMMEÈ
(AAVP), formed in 2000, is a network of 
African HIV vaccine stakeholders, led 
by Africans across the continent, with a 
vision of an African continent without 
AIDS.
sÈ !!60ÈSUPPORTSÈANDÈREPRESENTSÈ
the diverse African communities 
involved in HIV vaccine research 
and development (R&D), and is an 
important unified voice for African 
stakeholders.
sÈ 4HISÈPAPERÈDESCRIBESÈWHATÈ!!60ÈISÈ
what it does, and its impact, successes, 
and challenges. Finally, we discuss 
where AAVP is heading to harmonize 
with the Global HIV Vaccine Enterprise 
and the dynamic HIV vaccine research 
field.
The Health in Action section is a forum for individuals 
or organizations to highlight their innovative 
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use in Africa. To meet the vision 
of an AIDS-free Africa through 
an effective vaccine, AAVP has 
strengthened the network of African 
HIV vaccine stakeholders through 
research, advocacy, partnership, and 
contribution to capacity strengthening 
and policy development. AAVP aims 
to ensure that African communities 
and Africans participating in the 
HIV vaccine development process 
are adequately supported, are well 
represented globally, and are equal 
partners playing a critical role in 
HIV vaccine development efforts. 
AAVP is supported by the World 
Health Organization (WHO) and 
the Joint United Nations Programme 
on HIV/AIDS (UNAIDS). AAVP is a 
partnership-based network, committed 
to working closely with all HIV vaccine 
partners and sharing its resources and 
capacity, consistent with the Global 
HIV Vaccine Enterprise. AAVP has 
been successful in raising funds from 
different sectors and countries for its 
activities since its inception. 
AAVP (Figure 1) is coordinated by 
a secretariat and a steering committee 
(SC). The secretariat is housed by the 
WHO Initiative for Vaccine Research 
and its HIV Vaccine Initiative, with 
plans for relocation to an African 
center in the future. This future 
secretariat will maintain close ties 
to WHO, but will also have strong 
collaborations and links to the Global 
HIV Vaccine Enterprise activities and 
planned secretariat in Africa. The 
AAVP SC is an advisory body comprised 
of senior African stakeholders in 
the field of HIV vaccines. The SC 
advises the secretariat on unique 
opportunities for collaboration, and 
provides strategic directions for AAVP. 
The SC also has representation from 
the international partners to facilitate 
networking, promote transparency, and 
consolidate global involvement.
AAVP operates and implements most 
of its activities through a network of 
collaborative centers (CCs), located at 
key institutions across the continent, 
selected for their extensive experience 
and comparative advantages to AAVP 
and their ability for technology transfer 
within the continent. There are five 
doi:10.1371/journal.pmed.0050236.g001
Figure 1. The AAVP Structure
GTN, Global Training Network.
doi:10.1371/journal.pmed.0050236.g002
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CCs, which reflect AAVP’s primary work 
areas: (1) regulatory issues; (2) ethics, 
law, and human rights; (3) biomedical 
research; (4) country-based strategic 
planning; and (5) communication and 
media. Table 1 shows their location 
and key functions. All CCs are guided 
by the following strategic directions: 
capacity strengthening, advocacy, policy 
development, increased community 
involvement, and networking (Figure 2). 
To ensure AAVP is adequately 
represented at a political level, 
Madame Jeannette Kagame, First 
Lady of Rwanda, has been appointed 
as AAVP’s “High Representative.” 
She is well versed in the issues of 
poverty-associated diseases, and has a 
high profile within Africa. The High 
Representative is expected to drive 
the program at a political level and 
act as AAVP’s “Ambassador” at various 
meetings and policy forums. The AAVP 
High Representative will work closely 
with the AAVP secretariat, the AAVP 
CCs, the secretariat of the Global HIV 
Vaccine Enterprise, and the relevant 
WHO structures that are set up to 
influence and advocate for countries—
e.g., the WHO External Relations 
Officer and the New Partnership for 
African Development (NEPAD; http://
www.nepad.org/) Focal Point. 
What Does AAVP Do?
As a network of African stakeholders 
in vaccine development, AAVP has the 
comparative advantage of being in a 
unique position to provide common 
African solutions across the diverse 
cultural and political environment on 
the continent. Africa’s participation 
must include all aspects of vaccine 
development: laboratory research, 
vaccine and trial design, cohort 
development, advocacy, ethical, and 
regulatory issues, and projections and 
strategies for use of any possible HIV 
vaccine. AAVP also has the advantage 
of impartiality in that it has no specific 
products in development itself; AAVP’s 
close linkage to WHO/UNAIDS with 
their experience in ethics, regulatory, 
and policy issues gives it greater 
leverage in this regard. 
Operating through the five CCs, 
AAVP addresses identified gaps, such as 
the lack of adequate global regulatory 
capacity and harmonization, which is 
a major impediment to the conduct 
of properly reviewed and monitored, 
high-quality HIV vaccine clinical 
trials. AAVP also recognizes that 
the development of an HIV vaccine 
requires significant attention to ethics, 
law, and human rights, and works at the 
interface of these fields with behavioral 
sciences to address the key issues in 
HIV vaccine R&D and trials. 
Furthermore, the AAVP vision 
requires that Africans be integral to 
all aspects of vaccine development. 
Increased African participation in HIV 
vaccine-related biomedical research 
is critical for true partnership and 
trust. AAVP strengthens and develops 
a broad base of African biomedical 
scientists and research clinicians, who 
are able to respond to relevant research 
questions and have the skills to secure 
further national and international 
funding in collaboration with their 
counterparts in the developed world. 
AAVP also assists countries with the 
development of country-specific vaccine 
R&D plans and ensures that these 
are integrated as part of the overall 
national AIDS control program of 
each country. Finally, AAVP focuses on 
increasing the capacity of stakeholders 
on the continent to communicate more 
effectively on HIV vaccines. 
Specific Projects, Impact, and 
Successes
AAVP achievements. Since its 
inception, AAVP has contributed 
significantly to a new level of visibility 
for African HIV vaccine activities and 
has played an important coordinating 
and networking role on the continent. 
AAVP has brought together various 
African HIV vaccine stakeholders from 
many countries, creating collaborations 
and training programs and organizing 
symposia addressing key issues relevant 
to Africa. One year after its formation, 
in the 2001 Abuja Declaration on HIV/
AIDS, Tuberculosis, and Malaria, the 
African Union Heads of State and 
Government committed themselves 
to supporting the development of 
an effective, affordable, accessible 
HIV vaccine relevant to Africa. They 
also pledged to support AAVP and 
its partners and institutions devoted 
to HIV vaccine research and testing 
in Africa. This event, similar to the 
endorsement of the Global HIV 
Vaccine Enterprise by the G8 [6], 
is significant, as it was the first time 
African leaders collectively and strongly 
endorsed a continent-based vaccine 
effort.
To date, AAVP has successfully 
expanded and increased training 
and capacity building in the areas of 
community and media education, 
ethics, laboratory, and good clinical 
and regulatory practices specific to HIV 
vaccine development. AAVP has also 
provided support to the development 
of national AIDS vaccine plans in 
Botswana, Cameroon, Côte d’Ivoire, 
Ethiopia, Kenya, Nigeria, Rwanda, 
Tanzania, Uganda, and Zambia, and to 
the involvement of community groups 
in preparation for HIV vaccine trials. 
AAVP has been instrumental in the 
development of regional networks and 
doi:10.1371/journal.pmed.0050236.g003
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collaborative partnerships with African 
HIV vaccine research stakeholders. 
It has facilitated an international 
discussion of the inclusion of 
adolescents in HIV vaccine trials [7], 
identified capacity needs of 35 African 
research ethics committees to review 
HIV vaccine trials [8], and developed 
discussion documents on topics such 
as enrollment of women in trials 
[9], intellectual property, and tissue 
transfer issues [10]. AAVP has provided 
technical and financial support to ten 
research projects implemented by 
young African scientists (e.g., [11]). In 
addition, AAVP has organized three 
forums to facilitate interaction between 
partners and stakeholders for the 
development of common policies and 
strategies and their integration into the 
global vaccine agenda.
Challenges
Changes in the global HIV vaccine 
environment. Since the creation 
of AAVP in 2000, there have been 
dramatic changes in the African and 
global HIV vaccine context. The HIV 
vaccine R&D agenda has become 
far more focused on countries most 
affected by the HIV pandemic, and 
investment in Africa has increased 
significantly. In addition, there has 
been a shift by vaccine developers 
towards vaccine candidates that better 
reflect the HIV-1 variants prevalent in 
Africa. One indicator of the increased 
focus on Africa can be seen in the 
number of countries conducting 
HIV vaccine trials. Only one country 
(Uganda) had conducted an HIV 
vaccine clinical trial prior to 2000 
[12], whereas by 2007, eight African 
countries had conducted HIV vaccine 
trials(http://www.iavireport.org/)
(Figure 3). In addition, the level of 
political support has also increased in 
many African countries.
Global changes in the field of 
HIV vaccines, to which AAVP has 
responded, have occurred within 
two major contexts. First, there has 
been a growing understanding by 
the international community of 
the need to work more closely with 
scientists, clinicians, communities, 
politicians, and other stakeholders in 
highly affected regions of the globe, 
as well as to work with more relevant 
vaccine technology platforms and 
HIV gene inserts. The move to shift 
greater financial support to developing 
countries has required increased 
capacity development and political 
support within developed countries. 
Second, the significant shift in global 
thinking associated with the Global 
HIV Vaccine Enterprise has changed 
the field. The Enterprise is an alliance 
of independent global HIV vaccine 
development partners, all of which 
have their own work plans, but share 
a commitment to working together 
in a more efficient, collaborative, and 
complementary manner to develop an 
HIV vaccine in the shortest possible 
time (http://www.hivvaccineenterprise.
org/) [13]. 
Where Is AAVP Heading?
In the next two to three years, 
AAVP will become an autonomous 
organization, with its secretariat 
based in Africa but with strong links 
to WHO/UNAIDS and the Global 
HIV Vaccine Enterprise. This move 
will bring AAVP closer to its partners 
Table 1. AAVP Collaborating Centers, Location, and Key Functions
Collaborating Center Location Key Functions
Regulatory issues Not yet determined; applications are requested 
to host this Center
Needs assessment and training of regulatory bodies in countries where HIV  sÈ
vaccine trials are already being conducted or where they are planned
Working with the various African and non-African regulatory bodies and  sÈ
international HIV vaccine developers to ensure that training courses and policy 
development programs are appropriate for developing country regulators
Working with WHO and regional regulatory bodies to advise on potential  sÈ
harmonization of regulatory processes
Ethics, law, and human rights School of Psychology, University of KwaZulu-
Natal, Pietermaritzburg, South Africa 
Networking and assessment of needs for capacity building and training sÈ
Development of policy and guidance documents and training of IRBs in Africa sÈ
Publications and REC/IRB training on key ethical issues relevant for Africa  sÈ
Conducting research into development of a model ethical-legal framework  sÈ
Biomedical research Hosted by a consortium of three institutions: The 
Laboratoire de Bacteriologie Virologie, Universite 
Cheikh Anta Diop CHU Le Dantec, Dakar, 
Senegal; the Institute of Infectious Disease and 
Molecular Medicine, University of Cape Town, 
South Africa; and the Uganda Virus Research 
Institute, Entebbe, Uganda
Assessment of research and training needs, focusing on countries involved in  sÈ
HIV vaccine-related research and clinical trials 
Training of African investigators and building of human and infrastructure  sÈ
capacity
Networking and support for selected research projects to generate information  sÈ
relevant for Africa
Dissemination of biomedical information across the continent
Country-based strategic planning WHO secretariat, Geneva, Switzerland Support for strategic planning and the development of national HIV vaccines  sÈ
plans
Development of a guidance document as a tool to help countries with their  sÈ
national HIV vaccine plans
Communication and media ACE Communication and Media, University of 
Nairobi, Kenya
Training for media and communication representatives, especially community  sÈ
representatives
Development of targeted communication and education tools sÈ
Links and networking between Anglophone, Francophone, and Lusophone  sÈ
African countries
Linking of African trial site communities involved in HIV vaccines, so as to  sÈ
facilitate sharing of information and experience on community-based issues in 
the field
IRB, institutional review board; REC, research ethics committee
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working in Africa and to African 
leadership, and will increase African 
ownership. The CCs will be central 
to AAVP’s activities, acting as hubs 
bringing together partners to address 
a shared plan aligned with the Global 
HIV Vaccine scientific plan. While 
biomedical research, communication 
and media, ethics, law, and human 
rights, and regulatory issues will be 
based at the CCs with coordination at 
the secretariat, country-based strategic 
planning will remain an activity of the 
secretariat working closely with WHO/
UNAIDS. An important strategic 
objective for AAVP will be to influence 
the global agenda for HIV vaccine 
R&D and, at the same time, to create 
stronger ties and partnerships between 
African researchers and institutions 
and the rest of the world. To that end, 
AAVP will explore the possibility of 
a close relationship with the Global 
HIV Vaccine Enterprise as a vehicle 
for positioning African HIV vaccine 
research internationally.
In summary, AAVP acts to serve the 
network of African stakeholders in the 
major global mobilization to discover 
an effective HIV vaccine. AAVP is 
entering a new phase of increased 
activities and exposure, subsequent to 
comprehensive external review and 
strategic planning processes. 
AAVP is firmly positioned to play 
a significant leadership role on the 
African continent as the voice of 
African stakeholders involved in 
HIV vaccine development. AAVP’s 
plans are responding to the changing 
HIV vaccine environment, and offer 
substantial added value to those 
working in Africa by focusing on 
areas where AAVP has a comparative 
advantage. AAVP looks forward to the 
next five years of enhanced activities 
and greater impact towards its vision 
of “an AIDS-free Africa through an 
effective vaccine.”   
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